These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 23939596)

  • 1. Diffusion tensor imaging detects treatment effects of FTY720 in experimental autoimmune encephalomyelitis mice.
    Wang X; Brieland JK; Kim JH; Chen YJ; O'Neal J; O'Neil SP; Tu TW; Trinkaus K; Song SK
    NMR Biomed; 2013 Dec; 26(12):1742-50. PubMed ID: 23939596
    [TBL] [Abstract][Full Text] [Related]  

  • 2. FTY720, sphingosine 1-phosphate receptor modulator, ameliorates experimental autoimmune encephalomyelitis by inhibition of T cell infiltration.
    Kataoka H; Sugahara K; Shimano K; Teshima K; Koyama M; Fukunari A; Chiba K
    Cell Mol Immunol; 2005 Dec; 2(6):439-48. PubMed ID: 16426494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fingolimod (FTY720), sphingosine 1-phosphate receptor modulator, shows superior efficacy as compared with interferon-β in mouse experimental autoimmune encephalomyelitis.
    Chiba K; Kataoka H; Seki N; Shimano K; Koyama M; Fukunari A; Sugahara K; Sugita T
    Int Immunopharmacol; 2011 Mar; 11(3):366-72. PubMed ID: 20955831
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Relapse of experimental autoimmune encephalomyelitis after discontinuation of FTY720 (Fingolimod) treatment, but not after combination of FTY720 and pathogenic autoantigen.
    Yoshida Y; Tsuji T; Fujita T; Kohno T
    Biol Pharm Bull; 2011; 34(6):933-6. PubMed ID: 21628899
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diffusion basis spectrum imaging detects and distinguishes coexisting subclinical inflammation, demyelination and axonal injury in experimental autoimmune encephalomyelitis mice.
    Wang X; Cusick MF; Wang Y; Sun P; Libbey JE; Trinkaus K; Fujinami RS; Song SK
    NMR Biomed; 2014 Jul; 27(7):843-52. PubMed ID: 24816651
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation.
    Choi JW; Gardell SE; Herr DR; Rivera R; Lee CW; Noguchi K; Teo ST; Yung YC; Lu M; Kennedy G; Chun J
    Proc Natl Acad Sci U S A; 2011 Jan; 108(2):751-6. PubMed ID: 21177428
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunosuppression with FTY720 is insufficient to prevent secondary progressive neurodegeneration in experimental autoimmune encephalomyelitis.
    Al-Izki S; Pryce G; Jackson SJ; Giovannoni G; Baker D
    Mult Scler; 2011 Aug; 17(8):939-48. PubMed ID: 21459808
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FTY720 rescue therapy in the dark agouti rat model of experimental autoimmune encephalomyelitis: expression of central nervous system genes and reversal of blood-brain-barrier damage.
    Foster CA; Mechtcheriakova D; Storch MK; Balatoni B; Howard LM; Bornancin F; Wlachos A; Sobanov J; Kinnunen A; Baumruker T
    Brain Pathol; 2009 Apr; 19(2):254-66. PubMed ID: 18540945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FTY720 ameliorates MOG-induced experimental autoimmune encephalomyelitis by suppressing both cellular and humoral immune responses.
    Papadopoulos D; Rundle J; Patel R; Marshall I; Stretton J; Eaton R; Richardson JC; Gonzalez MI; Philpott KL; Reynolds R
    J Neurosci Res; 2010 Feb; 88(2):346-59. PubMed ID: 19658199
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CXCR7 antagonism prevents axonal injury during experimental autoimmune encephalomyelitis as revealed by in vivo axial diffusivity.
    Cruz-Orengo L; Chen YJ; Kim JH; Dorsey D; Song SK; Klein RS
    J Neuroinflammation; 2011 Dec; 8():170. PubMed ID: 22145790
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FTY720 sustains and restores neuronal function in the DA rat model of MOG-induced experimental autoimmune encephalomyelitis.
    Balatoni B; Storch MK; Swoboda EM; Schönborn V; Koziel A; Lambrou GN; Hiestand PC; Weissert R; Foster CA
    Brain Res Bull; 2007 Oct; 74(5):307-16. PubMed ID: 17845905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Brain penetration of the oral immunomodulatory drug FTY720 and its phosphorylation in the central nervous system during experimental autoimmune encephalomyelitis: consequences for mode of action in multiple sclerosis.
    Foster CA; Howard LM; Schweitzer A; Persohn E; Hiestand PC; Balatoni B; Reuschel R; Beerli C; Schwartz M; Billich A
    J Pharmacol Exp Ther; 2007 Nov; 323(2):469-75. PubMed ID: 17682127
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [New therapeutic approach for autoimmune diseases by the sphingosine 1-phosphate receptor modulator, fingolimod (FTY720)].
    Chiba K
    Yakugaku Zasshi; 2009 Jun; 129(6):655-65. PubMed ID: 19483408
    [TBL] [Abstract][Full Text] [Related]  

  • 14. FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system.
    Brinkmann V
    Br J Pharmacol; 2009 Nov; 158(5):1173-82. PubMed ID: 19814729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Targeting S1P receptors in experimental autoimmune encephalomyelitis in mice improves early deficits in locomotor activity and increases ultrasonic vocalisations.
    Sheridan GK; Dev KK
    Sci Rep; 2014 May; 4():5051. PubMed ID: 24851861
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel oxazolo-oxazole derivatives of FTY720 reduce endothelial cell permeability, immune cell chemotaxis and symptoms of experimental autoimmune encephalomyelitis in mice.
    Imeri F; Fallegger D; Zivkovic A; Schwalm S; Enzmann G; Blankenbach K; Meyer zu Heringdorf D; Homann T; Kleuser B; Pfeilschifter J; Engelhardt B; Stark H; Huwiler A
    Neuropharmacology; 2014 Oct; 85():314-27. PubMed ID: 24863045
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oral fingolimod rescues the functional deficits of synapses in experimental autoimmune encephalomyelitis.
    Rossi S; Lo Giudice T; De Chiara V; Musella A; Studer V; Motta C; Bernardi G; Martino G; Furlan R; Martorana A; Centonze D
    Br J Pharmacol; 2012 Feb; 165(4):861-9. PubMed ID: 21740406
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sequential phases of RGC axonal and somatic injury in EAE mice examined using DTI and OCT.
    Nishioka C; Liang HF; Barsamian B; Sun SW
    Mult Scler Relat Disord; 2019 Jan; 27():315-323. PubMed ID: 30469023
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-inflammatory effects of FTY720 do not prevent neuronal cell loss in a rat model of optic neuritis.
    Rau CR; Hein K; Sättler MB; Kretzschmar B; Hillgruber C; McRae BL; Diem R; Bähr M
    Am J Pathol; 2011 Apr; 178(4):1770-81. PubMed ID: 21406175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [A new therapeutic approach for autoimmune diseases by the sphingosine 1-phosphate receptor modulator, fingolimod (FTY720)].
    Chiba K
    Nihon Rinsho Meneki Gakkai Kaishi; 2009 Apr; 32(2):92-101. PubMed ID: 19404007
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.